Ryan E. Yaggie
Northwestern University
24 Papers
166 Citations
Ryan E. Yaggie is an academic researcher from Northwestern University. The author has contributed to research in topics: Pelvic pain & Acyloxyacyl hydrolase. The author has an hindex of 11, co-authored 23 publications. Previous affiliations of Ryan E. Yaggie include University of Iowa.
Chat about Author
Papers
Bacteria-induced uroplakin signaling mediates bladder response to infection.
Praveen Thumbikat,Ruth E. Berry,Ge Zhou,Benjamin K. Billips,Ryan E. Yaggie,Tetiana Zaichuk,Tung-Tien Sun,Anthony J. Schaeffer,David J. Klumpp +8 more
TL;DR: Bacteria-induced UPIIIa signaling is a critical mediator of bladder responses to insult by uropathogenic E. coli and pharmacological inhibition of these signaling events abrogates bacterial invasion and urothelial apoptosis in vitro and in vivo.
Stool-based biomarkers of interstitial cystitis/bladder pain syndrome
Andrea Braundmeier-Fleming,Nate Russell,Wenbin Yang,Megan Y. Nas,Ryan E. Yaggie,Matthew Berry,Laurie Bachrach,Sarah C. Flury,Darlene S. Marko,Colleen Bushell,Michael Welge,Bryan A. White,Anthony J. Schaeffer,David J. Klumpp +13 more
TL;DR: Stool metabolomic studies identified glyceraldehyde as significantly elevated in IC and metabolic pathway analysis identified lipid pathways, consistent with predicted metagenome functionality, suggest that DIPP species and metabolites may serve as candidates for novel IC biomarkers in stool.
A Live-Attenuated Vaccine for the Treatment of Urinary Tract Infection by Uropathogenic Escherichia coli
TL;DR: NU14 DeltawaaL is a candidate live-attenuated vaccine for the treatment and prevention of acute and recurrent urinary tract infection by caused by uropathogenic E. coli.
63
O-Antigen Modulates Infection-Induced Pain States
Charles N. Rudick,M. C. Jiang,Ryan E. Yaggie,Vladimir I. Pavlov,Joseph D. Done,Charles J. Heckman,Christopher Whitfield,Anthony J. Schaeffer,David J. Klumpp +8 more
TL;DR: Findings suggest that O-antigen functions as a rheostat to modulate LPS-associated pain, which has implications for an infectious etiology of chronic pain and evolutionary modification of pathogens to alter host behaviors.
A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic escherichia coli
Abstract: Uropathogenic Escherichia coli are the leading cause of urinary tract infection. We recently demonstrated that deletion of the O antigen ligase gene, waaL, from the uropathogenic E. coliisolate NU14 results in a strain that stimulates enhanced urothelial cytokine secretion. Because enhanced innate immune responses are of interest in vaccine development, we examined the therapeutic potential of NU14 DeltawaaL as a vaccine for urinary tract infection. NU14 DeltawaaL stimulated enhanced interleukin-6 secretion by mouse macrophages, compared with secretion by the wild type. Mice vaccinated via instillation into the bladder developed protective responses that prevented persistent colonization after bladder challenge with NU14, yet NU14 DeltawaaL failed to persistently colonize the mouse bladder. Inoculation with the vaccine strain protected mice against challenge with a broad range of clinical uropathogenic E. coli isolates and produced immunity that lasted 8 weeks. Therefore, NU14 DeltawaaL is a candidate live-attenuated vaccine for the treatment and prevention of acute and recurrent urinary tract infection by caused by uropathogenic E. coli.
39